NCT00471224

Brief Summary

This protocol intends to detail investigations necessary to evaluate the ocular safety of subjects enrolled in study A4321001 and who have received formulated Drug Product (Lot 8716-098).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
16

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2007

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 7, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 9, 2007

Completed
23 days until next milestone

Study Start

First participant enrolled

June 1, 2007

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2008

Completed
Last Updated

February 17, 2011

Status Verified

February 1, 2011

Enrollment Period

1.4 years

First QC Date

May 7, 2007

Last Update Submit

February 16, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • follow up for ocular safety and clinical features of ocular siderosis

    12 months

Secondary Outcomes (2)

  • ERG changes

    12 months

  • Anterior segment and fundal photography

    12 months

Study Arms (1)

Patients who have received drug.

Patients who have received drug.

Other: Observational Trial

Interventions

No intervention is being used in this study.

Patients who have received drug.

Eligibility Criteria

Age55 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A subset of subjects enrolled in study A4321001 and who have received formulated drug product.

You may qualify if:

  • A subset of subjects enrolled in study A4321001 and who have received formulated drug product (Lot 8716-098) will be included in the safety follow up study.

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Pfizer Investigational Site

Boston, Massachusetts, 02114, United States

Location

Pfizer Investigational Site

Charlotte, North Carolina, 28210, United States

Location

Pfizer Investigational Site

Houston, Texas, 77030, United States

Location

Related Links

MeSH Terms

Conditions

Siderosis

Interventions

Observation

Condition Hierarchy (Ancestors)

PneumoconiosisLung Diseases, InterstitialLung DiseasesRespiratory Tract DiseasesLung InjuryOccupational Diseases

Intervention Hierarchy (Ancestors)

MethodsInvestigative Techniques

Study Officials

  • Pfizer CT.gov Call Center

    Pfizer

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

May 7, 2007

First Posted

May 9, 2007

Study Start

June 1, 2007

Primary Completion

November 1, 2008

Study Completion

November 1, 2008

Last Updated

February 17, 2011

Record last verified: 2011-02

Locations